PHARMACY

Sandoz contraceptive granted regulatory approval

BY Alaric DeArment

PRINCETON, N.J. — The Food and Drug Administration has approved a generic contraceptive made by Sandoz, the company said.

Sandoz, the generics arm of Swiss drug maker Novartis, announced the FDA approval of Introvale (levonorgestrel and ethinyl estradiol), a generic version of Duramed’s Seasonale.

Branded and generic versions of Seasonale had sales of around $91 million during the 12-month period ended in November, according to IMS Health.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

PHARMACY

Pfizer forms licensing agreement with Seattle Genetics

BY Alaric DeArment

BOTHELL, Wash. — Pfizer has paid Seattle Genetics $8 million to license its antibody technology, Seattle Genetics said Thursday.

Seattle Genetics, based in Bothell, Wash., said Pfizer would pursue antibodies for treating an unspecified form of cancer using its antibody-drug conjugate technology. ADCs are monoclonal antibodies that selectively deliver anti-cancer agents to tumor cells. Seattle Genetics has developed anti-tumor drugs called auristatins, which are attached to antibodies and then used to kill the cancer cells while sparing noncancer cells.

Under the deal, Pfizer is responsible for research, product development, manufacturing and commercialization of any products created under the collaboration, and Seattle Genetics is eligible to receive milestones of more than $200 million, as well as royalties on sales.

“This collaboration reflects the increasing value of our ADC technology and strong interest in its potential among leaders in the drug development community,” Seattle Genetics chief business officer Eric Dobmeier said. “We now have 10 ongoing ADC collaborations, six collaborator ADCs using our technology are in clinical development and several additional programs are advancing toward the clinic.”

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

PHARMACY

Kombiglyze XR now available

BY Alaric DeArment

PRINCETON, N.J. — A new oral treatment for Type 2 diabetes hit the shelves Friday.

Bristol-Myers Squibb and AstraZeneca announced the availability of Kombiglyze XR (saxagliptin and metformin hydrochloride), which the companies called the only once-daily treatment for diabetes that combined metformin with a DPP-4 inhibitor, the drug class to which saxagliptin belongs.

The drug is designed for use alongside diet and exercise to improve glycemic control in adults with Type 2 diabetes.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES